Please wait a minute...
Shopping Cart Email List Chinese
Advanced Search Fig/Tab
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Featured Articles  |  Most Downloaded  |  Most Reading
Online Submission Subscribe to Our RSS Content Feed
Front. Med.    2020, Vol. 14 Issue (2) : 210-214    https://doi.org/10.1007/s11684-020-0757-x
CASE REPORT
Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19
Li Ni1, Ling Zhou1, Min Zhou2, Jianping Zhao2, Dao Wen Wang1()
1. Division of Cardiology;
2. Division of Respiration, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
 Download: PDF(951 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract

In December 2019, an outbreak of novel coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to ~2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.
Keywords novel coronavirus (2019-nCoV)      COVID-19      Chinese traditional patent medicine      Shuanghuanglian oral liquid     
Corresponding Author(s): Dao Wen Wang   
Just Accepted Date: 19 February 2020   Online First Date: 16 March 2020    Issue Date: 09 May 2020
 Cite this article:   
Li Ni,Ling Zhou,Min Zhou, et al. Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19[J]. Front. Med., 2020, 14(2): 210-214.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-020-0757-x
https://academic.hep.com.cn/fmd/EN/Y2020/V14/I2/210
Fig.1  Chest CT images of case 1. (A) CT imaging on January 23, 2020 shows ground glass opacity in both lungs on illness day 7. (B) Image taken on January 28, 2020, shows aggravation of pneumonia on illness day 12. (C) Image taken on February 6, 2020 shows the absorption of bilateral ground glass opacity after SHL treatment from January 28.
Specimen Case 1 Case 2 Case 3
Illness day 12 Illness day 20 Illness day 23 Illness day 3 Illness day 11 Illness day 14 Illness day 3 Illness day 11
Nasopharyngeal swab Negative Negative NT Negative Negative NT Positive Negative
Anal swab NT NT Negative NT NT Negative NT NT
Tab.1  Testing results of 2019-nCoV
Fig.2  Symptoms, maximum body temperatures, and treatment timeline in accordance with day of illness and day of hospitalization (January 17 to February 10).
Measure Reference range Illness day 13 Illness day 24
Hospital day 2 Hospital day 13
White cell count (×109/L) 3.50–9.50 5.93 5.46
Red cell count (×109/L) 3.80–5.10 4.13 4.06
Neutrophil count (×109/L) 1.90–6.30 3.04 3.27
Lymphocyte count (×109/L) 1.10–3.20 2.11 1.5
Eosinophil count (×109/L) 0.02–0.52 0.12 0.15
Platelet count (×109/L) 125.0–350.0 361 323
Hemoglobin (g/L) 115.0–150.0 113 111
Hematocrit (%) 35.0–45.0 35 35
Sodium (mmol/L) 136–214 140 140.4
Potassium (mmol/L) 3.50–5.10 4.22 4.8
Chloride (mmol/L) 99–110 104.6 102.4
Calcium (mmol/L) 2.15–2.50 2.06 ↓ 2.19
Carbon dioxide (mmol/L) 22.0–29.0 21 ↓ 25.1
Glucose (mmol/L) 4.11–6.05 – 5.01
Blood urea nitrogen (mmol/L) 2.6–7.5 3.1 3.6
Creatinine (mmol/L) 45–84 53 60
Total protein (g/L) 64–83 68.4 68.6
Albumin (g/L) 35–52 29.6 ↓ 33.2 ↓
Total bilirubin (mmol/L) ≤21 6.4 4.5
Procalcitonin (ng/mL) ≤0.05 0.03 0.03
Alanine aminotransferase (U/L) ≤33 17 20
Aspartate aminotransferase (U/L) ≤32 16 19
Alkaline phosphatase (U/L) 35–105 59 83
Fibrinogen (g/L) 2.00–4.00 5.31 ↑ –
Lactate dehydrogenase (U/L) 135–214 248 ↑ –
Prothrombin time (s) 11.5–14.5 13.6 –
International normalized ratio 0.80–1.20 1.03 –
Creatine kinase (U/L) ≤170 35 27
C-reactive protein (mg/L) ≤3 57.8 ↑ –
Tab.2  Clinical laboratory results of case 1
Fig.3  Chest CT images of case 2. (A) CT imaging obtained from case 2 on January 28, 2020 shows consolidation shadow in the left lung on illness day 3. (B) Image taken on February 6, 2020 shows the absorption of consolidation shadow after SHL treatment from January 28.
Measure Reference range Illness day 4 Illness day 15
Hospital day 2 Hospital day 13
White cell count (×109/L) 3.50–9.50 3.63 5.79
Red cell count (×109/L) 3.80–5.10 4.5 4.28
Neutrophil count (×109/L) 1.90–6.30 2.12 3.2
Lymphocyte count (×109/L) 1.10–3.20 1.25 1.98
Eosinophil count (×109/L) 0.02–0.52 0.01 0.17
Platelet count (×109/L) 125.0–350.0 139 308
Hemoglobin (g/L) 115.0–150.0 125 117
Hematocrit (%) 35.0–45.0 37.9 36.2
Sodium (mmol/L) 136–214 135.3 143.5
Potassium (mmol/L) 3.50–5.10 3.69 4.27
Chloride (mmol/ L) 99–110 97 ↓ 106.3
Calcium (mmol/L) 2.15–2.50 2.25 2.27
Carbon dioxide (mmol/L) 22.0–29.0 22.3 25.2
Glucose (mmol/L) 4.11–6.05 4.31 4.82
Blood urea nitrogen (mmol/L) 2.6–7.5 2.7 3.4
Creatinine (mmol/L) 45–84 59 52
Total protein (g L) 64–83 77.2 65.6
Albumin (g/L) 35–52 41.5 37.5
Total bilirubin (mmol/L) ≤21 6.6 4
Procalcitonin (ng/mL) ≤0.05 0.04 –
Alanine aminotransferase (U/L) ≤33 8 50 ↑
Aspartate aminotransferase (U/L) ≤32 21 27
Alkaline phosphatase (U/L) 35–105 52 22 ↓
Fibrinogen (g/L) 2.00–4.00 3.42 –
Lactate dehydrogenase (U/L) 135–214 170 186
Prothrombin time (s) 11.5–14.5 13.6 –
International normalized ratio 0.80–1.20 1.03 –
Creatine kinase (U/L) ≤170 52 27
C-reactive protein (mg/L) ≤3 9.4 ↑ –
Tab.3  Clinical laboratory results of case 2
Fig.4  Chest CT images of case 3. (A) CT imaging obtained from case 3 on January 28, 2020 shows ground glass opacity in the left lung on illness day 3. (B) Image taken on February 7, 2020 shows the absorption of ground glass opacity after SHL treatment from January 28.
1 N Zhu, D Zhang, W Wang, X Li, B Yang, J Song, X Zhao, B Huang, W Shi, R Lu, P Niu, F Zhan, X Ma, D Wang, W Xu, G Wu, GF Gao, W; Tan China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382(8): 727–733
https://doi.org/10.1056/NEJMoa2001017 pmid: 31978945
2 Q Li, X Guan, P Wu, X Wang, L Zhou, Y Tong, R Ren, KSM Leung, EHY Lau, JY Wong, X Xing, N Xiang, Y Wu, C Li, Q Chen, D Li, T Liu, J Zhao, M Liu, W Tu, C Chen, L Jin, R Yang, Q Wang, S Zhou, R Wang, H Liu, Y Luo, Y Liu, G Shao, H Li, Z Tao, Y Yang, Z Deng, B Liu, Z Ma, Y Zhang, G Shi, TTY Lam, JTK Wu, GF Gao, BJ Cowling, B Yang, GM Leung, Z Feng. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020 Jan 29. [Epub ahead of print] doi: 10.1056/NEJMoa2001316
https://doi.org/10.1056/NEJMoa2001316 pmid: 31995857
3 National Health Commission of the People’s Republic of China. Latest update on Novel Coronavirus Pneumonia as of 24:00, February 14, 2020. 2020. (in Chinese) (accessed February 15, 2020)
4 ML Holshue, C DeBolt, S Lindquist, KH Lofy, J Wiesman, H Bruce, C Spitters, K Ericson, S Wilkerson, A Tural, G Diaz, A Cohn, L Fox, A Patel, SI Gerber, L Kim, S Tong, X Lu, S Lindstrom, MA Pallansch, WC Weldon, HM Biggs, TM Uyeki, SK; Pillai Washington State 2019-nCoV Case Investigation Team. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020 Jan 31. [Epub ahead of print] doi: 10.1056/NEJMoa2001191
https://doi.org/10.1056/NEJMoa2001191 pmid: 32004427
5 JF Chan, S Yuan, KH Kok, KK To, H Chu, J Yang, F Xing, J Liu, CC Yip, RW Poon, HW Tsoi, SK Lo, KH Chan, VK Poon, WM Chan, JD Ip, JP Cai, VC Cheng, H Chen, CK Hui, KY Yuen. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395(10223): 514–523
https://doi.org/10.1016/S0140-6736(20)30154-9 pmid: 31986261
[1] Zixin Shu, Yana Zhou, Kai Chang, Jifen Liu, Xiaojun Min, Qing Zhang, Jing Sun, Yajuan Xiong, Qunsheng Zou, Qiguang Zheng, Jinghui Ji, Josiah Poon, Baoyan Liu, Xuezhong Zhou, Xiaodong Li. Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases[J]. Front. Med., 2020, 14(6): 760-775.
[2] Guohua Chen, Wen Su, Jiayao Yang, Dan Luo, Ping Xia, Wen Jia, Xiuyang Li, Chuan Wang, Suping Lang, Qingbin Meng, Ying Zhang, Yuhe Ke, An Fan, Shuo Yang, Yujiao Zheng, Xuepeng Fan, Jie Qiao, Fengmei Lian, Li Wei, Xiaolin Tong. Chinese herbal medicine reduces mortality in patients with severe and critical coronavirus disease 2019: a retrospective cohort study[J]. Front. Med., 2020, 14(6): 752-759.
[3] Qingwei Li, Han Wang, Xiuyang Li, Yujiao Zheng, Yu Wei, Pei Zhang, Qiyou Ding, Jiaran Lin, Shuang Tang, Yikun Zhao, Linhua Zhao, Xiaolin Tong. The role played by traditional Chinese medicine in preventing and treating COVID-19 in China[J]. Front. Med., 2020, 14(5): 681-688.
[4] Mian Peng, Xueyan Liu, Jinxiu Li, Di Ren, Yongfeng Liu, Xi Meng, Yansi Lyu, Ronglin Chen, Baojun Yu, Weixiong Zhong. Successful management of seven cases of critical COVID-19 with early noninvasive–invasive sequential ventilation algorithm and bundle pharmacotherapy[J]. Front. Med., 2020, 14(5): 674-680.
[5] Lingling Tang, Yingan Jiang, Mengfei Zhu, Lijun Chen, Xiaoyang Zhou, Chenliang Zhou, Peng Ye, Xiaobei Chen, Baohong Wang, Zhenyu Xu, Qiang Zhang, Xiaowei Xu, Hainv Gao, Xiaojun Wu, Dong Li, Wanli Jiang, Jingjing Qu, Charlie Xiang, Lanjuan Li. Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19[J]. Front. Med., 2020, 14(5): 664-673.
[6] Zhihang Peng, Wenyu Song, Zhongxing Ding, Quanquan Guan, Xu Yang, Qiaoqiao Xu, Xu Wang, Yankai Xia. Linking key intervention timings to rapid declining effective reproduction number to quantify lessons against COVID-19[J]. Front. Med., 2020, 14(5): 623-629.
[7] Chen Xu, Yinqiao Dong, Xiaoyue Yu, Huwen Wang, Lhakpa Tsamlag, Shuxian Zhang, Ruijie Chang, Zezhou Wang, Yuelin Yu, Rusi Long, Ying Wang, Gang Xu, Tian Shen, Suping Wang, Xinxin Zhang, Hui Wang, Yong Cai. Estimation of reproduction numbers of COVID-19 in typical countries and epidemic trends under different prevention and control scenarios[J]. Front. Med., 2020, 14(5): 613-622.
[8] Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie, Zhisheng Huang, Lixue Huang, Xiaoying Gu, Hui Li, Yi Zhang, Yimin Wang, Frederick G. Hayden, Peter W. Horby, Bin Cao, Chen Wang. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis[J]. Front. Med., 2020, 14(5): 601-612.
[9] Zhengqian Li, Taotao Liu, Ning Yang, Dengyang Han, Xinning Mi, Yue Li, Kaixi Liu, Alain Vuylsteke, Hongbing Xiang, Xiangyang Guo. Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain[J]. Front. Med., 2020, 14(5): 533-541.
[10] Cenyi Shao, Shijian Li, Feng Zhu, Dahai Zhao, Hui Shao, Haixiao Chen, Zhiruo Zhang. Taizhou’s COVID-19 prevention and control experience with telemedicine features[J]. Front. Med., 2020, 14(4): 506-510.
[11] Guangbiao Zhou, Saijuan Chen, Zhu Chen. Advances in COVID-19: the virus, the pathogenesis, and evidence-based control and therapeutic strategies[J]. Front. Med., 2020, 14(2): 117-125.
[12] Yong Li, Fan He, Ning Zhou, Jia Wei, Zeyang Ding, Luyun Wang, Peng Chen, Shuiming Guo, Binhao Zhang, Xiaoning Wan, Wei Zhu, on behalf of Multidisciplinary Team for COVID-19, Optical Valley Branch of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Organ function support in patients with coronavirus disease 2019: Tongji experience[J]. Front. Med., 2020, 14(2): 232-248.
[13] Zhiruo Zhang, Shelan Liu, Mi Xiang, Shijian Li, Dahai Zhao, Chaolin Huang, Saijuan Chen. Protecting healthcare personnel from 2019-nCoV infection risks: lessons and suggestions[J]. Front. Med., 2020, 14(2): 229-231.
[14] Fanghua Gong, Yong Xiong, Jian Xiao, Li Lin, Xiaodong Liu, Dezhong Wang, Xiaokun Li. China’s local governments are combating COVID-19 with unprecedented responses ---- from a Wenzhou governance perspective[J]. Front. Med., 2020, 14(2): 220-224.
[15] Shuxian Zhang, Zezhou Wang, Ruijie Chang, Huwen Wang, Chen Xu, Xiaoyue Yu, Lhakpa Tsamlag, Yinqiao Dong, Hui Wang, Yong Cai. COVID-19 containment: China provides important lessons for global response[J]. Front. Med., 2020, 14(2): 215-219.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed